Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, applauded the recommendation that the treatment of CV risk in patients with hypertriglyceridemia be part of a broader dyslipidemia management as discussed in the 2026 American College of Cardiology (ACC) / American Heart Association (AHA)/Multisociety Dyslipidemia Guideline Update.i 

These newly-issued, evidenced-based recommendations summarize the clinical role of icosapent ethyl (IPE) in reducing cardiovascular (CV) risk in statin-treated patients with elevated triglycerides (TG) and fully align with Amarin's commitment to addressing the burden of CV disease across the healthcare ecosystem.ii 

Patients at high CV risk frequently fail to achieve LDL‑C targets, and few receive evidence‑based adjunct therapies.iii,iv This updated dyslipidemia guideline reflects a shift in CV care, toward lifelong, prevention-first management, encouraging earlier screening and a broader approach to risk reduction beyond low-density lipoprotein (LDL-C) alone to address drivers of residual or persistent CV risk. Importantly, the guideline recognizes that achieving LDL-C targets does not eliminate cardiovascular risk, and that many patients continue to experience CV events despite optimized statin therapy.

The updated guideline reinforces that patients on statin therapy can experience residual CV risk driven by elevated TG levels - a significant clinical challenge affecting millions of Americans. According to the guideline, elevated TG levels contribute meaningfully to CV disease burden and ongoing cardiovascular events even in patients achieving LDL cholesterol targets, underscoring the need for complementary therapeutic approaches beyond statin monotherapy.

Amarin's VASCEPA®/VAZKEPA® (icosapent ethyl) is an effective, safe, oral therapy that has been prescribed more than 30 million times globally. It is the first and only FDA-approved oral therapy proven to reduce the risk of CV events (such as a heart attack or stroke) by 25% when added on top of recommended statin therapy in high-risk patients with elevated and high TG levels.

Importantly, the guideline distinguishes therapies aimed at pancreatitis prevention from those proven to reduce atherosclerotic cardiovascular disease (ASCVD) events, reinforcing that CV outcomes - not biomarker changes alone - must guide treatment decisions. For patients who remain at elevated CV risk despite optimized statin therapy, the guideline supports the addition of evidence-based therapies specifically proven to reduce cardiovascular events, such as icosapent ethyl (IPE). This position is consistent with guidance from other cardiovascular societies, including the 2025 ESC/EAS Dyslipidemias guideline focused update which states that "high-dose icosapent ethyl (as in the REDUCE-IT trial) should be considered for high-risk or very high-risk patients with elevated triglyceride levels (fasting triglyceride level 135–499 mg/dL [1.52–5.63 mmol/L]) despite statin therapy to lower CVD events." Together, these guideline updates reflect growing global consensus around the importance of addressing residual cardiovascular risk beyond LDL-C lowering alone.